We have previously shown that streptozotocin (STZ) inhibits O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase (O-GlcNAcase), the enzyme that removes O-GlcNAc from proteins. In light of this observation, we explored the possibility that the diabetogenic toxin alloxan, an O-GlcNAc transferase (OGT) inhibitor, might also inhibit O-GlcNAcase. Alloxan inhibited islet O-GlcNAcase with a dose-response much like that of STZ. Similar to STZ, islet O-GlcNAcase was more susceptible to alloxan inhibition than was brain O-GlcNAcase. Alloxan directly inhibited recombinant O-GlcNAcase activity with a dose-response very similar to that of STZ. Subsequent LC/MS/MS analysis revealed that alloxan modified the tryptic digest pattern of the enzyme. One tryptic peptide LGCFEIAK(894-901) was modified by alloxan. Two other tryptic peptides, LDQVSQFGCR(158-167) and SFALLFDDIDHNMCAADK(168-185), both N-terminal active site peptides, were absent after alloxan treatment. Together, these data demonstrate that alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase, with inhibition corresponding to an altered tryptic digest pattern of N-terminal active site peptides.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2006.09.155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting O-glycosyltransferase (OGT) to promote healing of diabetic skin wounds.
J Biol Chem
February 2014
From the Departments of Dermatology and.
Non-healing wounds are a significant source of morbidity. This is particularly true for diabetic patients, who tend to develop chronic skin wounds. O-GlcNAc modification of serine and threonine residues is a common regulatory post-translational modification analogous to protein phosphorylation; increased intracellular protein O-GlcNAc modification has been observed in diabetic and hyperglycemic states.
View Article and Find Full Text PDFO-GlcNAc-selective-N-acetyl-beta-D-glucosaminidase activity and mRNA expression in muscle is related to glucosamine-induced insulin resistance.
Pharmacology
October 2010
Unidad de Investigación Médica en Bioquímica, Centro Médico Nacional Siglo XXI, México DF, México.
Glucosamine (GlcN)-induced insulin resistance is associated with an increase in O-linked-N-acetylglucosaminylated modified proteins (O-GlcNAcylated proteins). The role played by O-GlcNAc-selective-N-acetyl-beta-D-glucosaminidase (O-GlcNAcase), which removes O-N-acetyl-glucosamine residues from O-GlcNAcylated proteins, has not yet been demonstrated. We investigated whether GlcN-induced whole-body insulin resistance is related to tissue O-GlcNAcase activity and mRNA expression.
View Article and Find Full Text PDFToxic effects of hyperglycemia are mediated by the hexosamine signaling pathway and o-linked glycosylation in early mouse embryos.
Biol Reprod
April 2010
The University of Queensland School of Biomedical Sciences, Brisbane, Queensland 4072, Australia.
Article Synopsis
- Maternal hyperglycemia is linked to early pregnancy loss and congenital malformations, likely due to its effects on the hexosamine signaling pathway (HSP) and O-GlcNAcylation during early embryonic development.
- An in vitro study used mouse zygotes exposed to different glucose levels and glucosamine to assess the impact on blastocyst formation, cell proliferation, and apoptosis, revealing that increased HSP flux from hyperglycemia negatively affected these parameters.
- Inhibiting key enzymes involved in O-GlcNAcylation reversed the detrimental effects of hyperglycemia, indicating that dysregulation of this signaling pathway plays a critical role in the negative outcomes observed in diabetic pregnancies.
Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase.
Biochem Biophys Res Commun
December 2006
Eli Lilly and Company, Indianapolis, IN 46285, USA.
We have previously shown that streptozotocin (STZ) inhibits O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase (O-GlcNAcase), the enzyme that removes O-GlcNAc from proteins. In light of this observation, we explored the possibility that the diabetogenic toxin alloxan, an O-GlcNAc transferase (OGT) inhibitor, might also inhibit O-GlcNAcase. Alloxan inhibited islet O-GlcNAcase with a dose-response much like that of STZ.
View Article and Find Full Text PDFThe diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase that contain amino acid residues essential for enzymatic activity.
Biochem Pharmacol
September 2006
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Streptozotocin (STZ) inhibits O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase (O-GlcNAcase), the enzyme that removes O-GlcNAc from proteins. The active site of the enzyme was recently proposed to include aspartates 174, 175, and 177, with STZ inhibition via a transition state analog. We explored the effect of STZ on the tryptic peptide digest pattern of O-GlcNAcase.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!